Edwards reports strong 2025 despite Q4 EPS miss

Edwards Lifesciences has reported gross implicit $6bn successful afloat twelvemonth 2025, predominantly driven by beardown request for its transcatheter aortic valve replacement (TAVR) products on with 56.4% maturation successful its transcatheter mitral and tricuspid therapies (TMTT) portfolio, contempt missing analysts’ net per stock (EPS) estimation successful Q4.

With 2025 gross reflecting an 11.5% uptick versus 2024 and with Q4 2025 gross of $1.56bn denoting a 13.3% emergence connected Q4 2024, Edwards expects 2026 net to autumn successful the $2.90 to $3.05 per stock scope and has acceptable its gross maturation guidance betwixt 8% and 10% astatine changeless currency.

Edwards financials released aft marketplace adjacent connected 10 February yet prompted a 3% emergence connected the company’s shares connected the New York Stock Exchange (NYSE) successful after-hours trading, according to Reuters. Edwards has a marketplace headdress of $44.71bn.

In 2025, Edwards’ TAVR portfolio contributed $4.49bn to its full revenue, corresponding to a 9.3% emergence from $4.10bn successful 2024.

Meanwhile, TMTT grew 56.4% to $550.6m successful 2025 versus $352.1m successful 2024. During a league call, Edwards CEO Bernard Zovighian highlighted that this maturation was fuelled by a “comprehensive portfolio of repair and replacement therapies” and strengthened by caller options for patients.

“These see the motorboat of SAPIEN M3, the scaling of EVOQUE, and the upcoming instauration of the adjacent procreation of PASCAL and PASCAL for US tricuspid patients besides successful Q4 2026,” Zovighian said.

“Together, these are important advancements for mitral and tricuspid patients and correspond ample opportunities to execute our $2bn gross anticipation for TMTT successful 2030,” Zovighian added.

Meanwhile, gross successful Edwards surgical structural bosom portfolio eclipsed $1bn successful 2025 and drew successful $253.6m successful Q4, representing respective year-over-year upticks of 4.9% and 3.8%.

Total Q4 gross came successful astatine $1.56bn. As with Edwards afloat twelvemonth results, its TAVR portfolio drew successful the bulk of gross astatine $1.16bn, denoting a 12% uptick connected astir $1bn successful Q4 2024. According to information compiled by London Stock Exchange Group (LSEG) and seen by Reuters, this show exceeded analysts’ estimates of $1.13bn.

Despite the affirmative Q4 performance, adjusted EPS of $0.58 successful the 4th fell abbreviated of analysts’ estimates of $0.62. However, successful a probe note, William Blair expert Brandon Vasquez highlighted that the EPS miss was mostly owed to a “deliberate increase” successful walk up of improving TAVR guidelines and perchance expanded reimbursement aboriginal successful 2026, investments the steadfast stated were “bullish for aboriginal growth”.